Delta Pulley Guard Max 86% OFF Assembly 426-02-627-0001 B For Stand Open 14" Guard,stonepaper.xyz,Open,For,/implosive1675742.html,14",Delta,426-02-627-0001,Pulley,$59,B,Assembly,Home & Garden , Tools & Workshop Equipment , Power Tool & Air Tool Replacemen,Stand $59 Delta Pulley Guard Assembly 426-02-627-0001 For 14" Open Stand B Home & Garden Tools & Workshop Equipment Power Tool & Air Tool Replacemen Delta Pulley Guard Max 86% OFF Assembly 426-02-627-0001 B For Stand Open 14" $59 Delta Pulley Guard Assembly 426-02-627-0001 For 14" Open Stand B Home & Garden Tools & Workshop Equipment Power Tool & Air Tool Replacemen Guard,stonepaper.xyz,Open,For,/implosive1675742.html,14",Delta,426-02-627-0001,Pulley,$59,B,Assembly,Home & Garden , Tools & Workshop Equipment , Power Tool & Air Tool Replacemen,Stand

Delta Pulley Guard Max 86% Ranking TOP4 OFF Assembly 426-02-627-0001 B For Stand Open 14

Delta Pulley Guard Assembly 426-02-627-0001 For 14" Open Stand B

$59

Delta Pulley Guard Assembly 426-02-627-0001 For 14" Open Stand B

|||

Item specifics

Condition:
Open box:
An item in excellent, new condition with no wear. The item may be missing the original packaging or protective wrapping, or may be in the original packaging but not sealed. The item includes original accessories. The item may be a factory second. See the seller's listing for full details and description.
Seller Notes:
“Includes Part # 426-02-054-0009 & # 426-02-054-0010”
Model:
426-02-054-0010
Part Type:
Guard
MPN:
426-02-054-0009
Brand:
Delta





Delta Pulley Guard Assembly 426-02-627-0001 For 14" Open Stand B

CURRENT ISSUE
May, 2022

No. 107 (5)

2020 Impact Factor: 9.941 Submission > Acceptance: 80 days
ARTICLES IN THREE SENTENCES
Article

Germline GATA2 variant disrupting endothelial eNOS function and angiogenesis can be restored by c-Jun/AP-1 upregulation

Germline GATA2 gene variants have been associated with several inherited and acquired hematologic disorders, and thrombosis has been reported in 25% of patients. Authors demonstrated that GATA2 deficiency is associated with defective expression of eNOS by platelets and endothelial cells with impaired NO production, suggesting that this may represent an important thrombogenic mechanism. They also identified a therapeutic option, through atorvastatin, able to restore eNOS expression and angiogenesis in GATA2 deficiency in vitro.

Giulio Purgatorio et al.

Letter

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity

This study includes all consecutive WHO-defined MDS/MPN patients of Mayo Clinic from 1994 to 2020.Next-generation sequencing information at diagnosis was available for 444 (57%) patients. Authors combined all SF3B1-mutant MDS/MPN patients into one category (n=78) and compared them to their wild-type counterparts (n=446). Leukemia-free survival and overall survival in MDS/MPN patients with SF3B1 mutations were significantly better compared to SF31B wild-type MDS/MPN patients.

Abhishek A. Mangaonkar et al.

Article

Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study

Data regarding efficacy and toxicity of CAR-T cell therapy in the elderly, geriatric population are insufficient. This study explored the characteristics and outcome of 47 consecutive patients, 70 years or older, referred for CAR-T. The outcomes of CAR-T cell therapy are comparable between elderly, geriatric and younger patients, indicating that age as per se should not preclude CAR-T cell administration.

Ron Ram et al.

Article

Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma

In this prospective pilot study, authors evaluated a rituximab/prednisone prephase treatment strategy in 33 older, vulnerable patients with newly diagnosed DLBCL. This prephase therapy was feasible with acceptable toxicity profiles and excellent long-term survival. Prephase therapy with rituximab/prednisone should be considered for all older, vulnerable DLBCL patients prior to curative intent, anthracycline-based chemoimmunotherapy.

Richard J. Lin et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA